Patents by Inventor Garrit-Jan Boudewijn van Ommen

Garrit-Jan Boudewijn van Ommen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230151362
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with an antisense molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such antisense molecule used in said method.
    Type: Application
    Filed: July 25, 2022
    Publication date: May 18, 2023
    Inventors: Josephus Johannes de Kimpe, Adriana Marie Rus, Gerard Johannes Platenburg, Judith Christina Theodora van Deutekom, Garrit-Jan Boudewijn van Ommen
  • Patent number: 11427820
    Abstract: The. invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with an antisense molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such antisense molecule used in said method.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: August 30, 2022
    Assignees: BioMarin Technologies B.V., Academisch Ziekenbuls Leiden
    Inventors: Josephus Johannes De Kimpe, Adriana Marie Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20210207138
    Abstract: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5?-GUGGCUAACAGAAGCU (SEQ ID NO:1), 5?-GGGAACAUGCUAAAUAC (SEQ ID NO:2), 5?-AGACACAAAUUCCUGAGA (SEQ ID NO:3), or 5?-CUGUUGAGAAA (SEQ ID NO. 4), and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
    Type: Application
    Filed: December 11, 2020
    Publication date: July 8, 2021
    Inventors: Gerard Johannes Platenburg, Josephus Johannes De Kimpe, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen, Annemieke Aartsma-Rus
  • Publication number: 20200332298
    Abstract: The invention relates to means and methods for removing a proteolytic cleavage site from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Application
    Filed: June 12, 2019
    Publication date: October 22, 2020
    Inventors: Wilhelmina M.C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20200239886
    Abstract: The. invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with an antisense molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such antisense molecule used in said method.
    Type: Application
    Filed: September 26, 2019
    Publication date: July 30, 2020
    Inventors: Josephus Johannes De Kimpe, Adriana Marie Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20200224203
    Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Application
    Filed: February 4, 2020
    Publication date: July 16, 2020
    Inventors: Wilhelmina M.C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Patent number: 10590421
    Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 17, 2020
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Wilhelmina M. C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20190292541
    Abstract: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5?GUGGCUAACAGAAGCU (SEQ ID NO 1) and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 26, 2019
    Inventors: Gerard Johannes Platenburg, Josephus Johannes De Kimpe, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen, Annemieke Aartsma-Rus
  • Patent number: 10364432
    Abstract: The invention relates to means and methods for removing a proteolytic cleavage site from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: July 30, 2019
    Assignee: Academisch Ziekenhuis Leiden h.o.d.n. LUMC
    Inventors: Wilhelmina M. C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20190177725
    Abstract: The. invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with an antisense molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such antisense molecule used in said method.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 13, 2019
    Inventors: Josephus Johannes De Kimpe, Adriana Marie Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20190119679
    Abstract: The. invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with an antisense molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such antisense molecule used in said method.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 25, 2019
    Inventors: Josephus Johannes De Kimpe, Adriana Marie Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20190112604
    Abstract: The. invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with an antisense molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such antisense molecule used in said method.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 18, 2019
    Inventors: Josephus Johannes De Kimpe, Adriana Marie Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Patent number: 10246707
    Abstract: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5?-GUGGCUAACAGAAGCU (SEQ ID NO 1) and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: April 2, 2019
    Assignees: Biomarin Technologies B.V., Academisch Ziekenhuis Leiden
    Inventors: Gerard Johannes Platenburg, Josephus Johannes de Kimpe, Judith Christina Theodora van Deutekom, Garrit-Jan Boudewijn van Ommen, Annemieke Aartsma-Rus
  • Patent number: 9926557
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolated muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: March 27, 2018
    Assignees: BioMarin Technologies B.V., Academisch Ziekenhuis Leiden
    Inventors: Josephus Johannes De Kimpe, Gerardus Johannes Platenburg, Judith Christina Theodora Van Deutekom, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Patent number: 9896687
    Abstract: The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: February 20, 2018
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN
    Inventors: Garrit-Jan Boudewijn van Ommen, Judith Christina Theodora van Deutekom, Johannes Theodorus den Dunnen, Annemieke Aartsma-Rus
  • Publication number: 20170226521
    Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Application
    Filed: April 21, 2017
    Publication date: August 10, 2017
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Wilhelmina M.C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20170175117
    Abstract: The invention relates to means and methods for removing a proteolytic cleavage site from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Application
    Filed: February 22, 2017
    Publication date: June 22, 2017
    Applicant: Academisch Ziekenhuis Leiden h.o.d.n. LUMC
    Inventors: Wilhelmina M.C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20170107512
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.
    Type: Application
    Filed: December 27, 2016
    Publication date: April 20, 2017
    Inventors: Josephus Johannes De KIMPE, Adriana Marie RUS, Gerard Johannes PLATENBURG, Judith Christina Theodora Van DEUTEKOM, Garrit-Jan Boudewijn Van OMMEN
  • Patent number: 9611471
    Abstract: Described are means and methods for removing a proteolytic cleavage site from a protein, the method comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, and allowing translation of mRNA produced from the pre-mRNA.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: April 4, 2017
    Assignee: Academisch Ziekenhuis Leiden
    Inventors: Wilhelmina M. C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Patent number: RE48468
    Abstract: The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: March 16, 2021
    Assignees: BioMarin Technologies B.V., Academisch Ziekenhuis Leiden
    Inventors: Josephus Johannes De Kimpe, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen